Osteoporos Int 19 May online 2015. DOI 10.1007/s00198-015-3160-8 Postmenopausal women aged 50 years and older with a recent DRF had lower bone and muscle strength in both the upper and lower extremities com- pared to … Leer más
JAMA Intern Med. Published online April 13, 2015. doi:10.1001/jamainternmed.2015.0747. In this group of frail elderly women with osteoporosis, 1 dose of zoledronic acid improved BMD over 2 years. The clinical importance of nonsignificant increases in … Leer más
JAMA Intern Med. Published online April 13, 2015. doi:10.1001/jamainternmed.2015.0757 In this issue of JAMA Internal Medicine, Greenspan and colleagues1 present intriguing data on zoledronic acid, one of the most potent drugs in the bisphosphonate family—if … Leer más
J Clin Endocrinol Metab. 2015 Apr;100(4):1343-9. doi: 10.1210/jc.2014-4166. Epub 2015 Feb 2. Arterialized plasma HCO3 was associated positively with cross-sectional BMD and inversely with the rate of bone loss, implying that systemic acid-base status is … Leer más
J Clin Endocrinol Metab. 2015 Apr;100(4):1237-40. doi: 10.1210/jc.2015-1396 Autor: Magge SN.
J Clin Invest. 2015 Apr;125(4):1509-22. doi: 10.1172/JCI77716. Epub 2015 Mar 9. Together, our results indicate that miR-188 is a key regulator of the age-related switch between osteogenesis and adipogenesis of BMSCs and may represent a … Leer más
The switch from tenofovir to abacavir seems to induce a positive effect on bone tissue, since bone turnover markers decreased. In addition, circulating sclerostin levels increased, a change associated with improved bone properties.
The tissue-selective estrogen complex (TSEC) combines bazedoxifene and conjugated estrogens and is designed not only to improve menopausal symptoms and vulvovaginal atrophy but also to prevent bone loss. Therefore, it maintains the benefits of estrogen … Leer más
JAMA. 2015 Apr 14;313(14):1467-1468. doi: 10.1001/jama.2015.1064. This JAMA Clinical Guidelines Synopsis article summarizes the most recent National Osteoporosis Foundation guidelines on screening older men and postmenopausal women for osteoporosis. Autor: Altkorn D, Cifu AS.
Sequential antiresorptive therapy is recommended to maintain drug increases in bone mass and support secondary mineralization of the newly formed bone. Combination therapies of antiresorptives and anabolic agents have shown a significant increase in bone … Leer más
